Early-stage lung adenocarcinoma is driven by an injury-associated, plastic cell state dependent on a KRAS-ITGA3-SRC axis

Aaron L. Moye,Antonella F. M. Dost,Robert Ietswaart,Shreoshi Sengupta,VanNashlee Ya,Chrystal Aluya,Caroline G. Fahey,Sharon M. Louie,Margherita Paschini,Carla F. Kim
DOI: https://doi.org/10.1101/2024.02.27.582165
2024-03-03
Abstract:Glycine 12 mutations in the GTPase KRAS (KRAS ) are a known initiating event for lung adenocarcinoma (LUAD) with broad clinical relevance. KRAS mutations promote cell-intrinsic rewiring of the lung alveolar type II progenitor (AT2) cells, but to what extent such changes interplay with pathways essential for lung homeostasis and cell fate is unclear. We used single-cell RNA-seq (scRNA-seq) from AT2-mesenchyme organoid co-cultures, mouse models, and stage IA LUAD patient samples to identify conserved regulators of AT2 cell transcriptional dynamics and the impact of KRAS with temporal resolution. In AT2 organoids, a transient injury/plasticity state preceded AT2 self-renewal and AT1 differentiation. Early-stage AT2 cells exhibited perturbed gene expression dynamics most noted by retention of the injury/plasticity state. At later time points in tumorigenesis, AT2 cells consisted of heterogeneous populations that could be defined by either the injury state or high expression of an AT2 cell signature. The injury state in AT2 cells of LUAD in patients, mice, and organoids was distinguishable from AT2 states by altered receptor expression, including co-expression of ITGA3 and SRC. The combination of clinically relevant KRAS and SRC inhibitors to target the oncogenic injury cell state impaired AT2 organoid growth. Thus, an injury/plasticity signature characterized as an essential step in lung repair is used during alveolar cell self-renewal and during initiation and progression of LUAD. Early-stage lung cancer may be susceptible to intervention by targeting the oncogenic-specific nature of this cell state.
Cancer Biology
What problem does this paper attempt to address?
The problems that this paper attempts to solve mainly focus on the occurrence mechanism of early - stage lung adenocarcinoma (LUAD) and its potential treatment strategies. Specifically, the research focuses on the following points: 1. **The role of KRAS mutations in LUAD**: The G12 mutation of the KRAS gene is a known initiating event in LUAD. It is currently unclear how these mutations affect the intrinsic reprogramming of alveolar type II progenitor cells (AT2 cells) and how this change interacts with the pathways that maintain lung homeostasis and determine cell fate. 2. **The injury/plasticity state of AT2 cells**: The research has found that AT2 cells will experience a transient injury/plasticity state before self - renewal and AT1 differentiation. However, in the context of KRAS mutations, whether this state is abnormally retained and how this retention promotes tumorigenesis are questions that need to be answered. 3. **The role of the KRAS - ITGA3 - SRC axis**: The research further explores whether KRAS - mutated AT2 cells drive tumorigenesis through specific signaling pathways (such as the KRAS - ITGA3 - SRC axis) and whether these pathways can be used as treatment targets for early - stage LUAD. 4. **Treatment strategies for early - stage LUAD**: Based on the above findings, the research explores whether the combination of KRAS inhibitors and SRC inhibitors (such as dasatinib) can effectively inhibit the growth of early - stage LUAD, thereby providing new treatment strategies. In summary, this paper aims to reveal the occurrence mechanism of early - stage LUAD by in - depth analysis of the impact of KRAS mutations on AT2 cells and explore potential treatment strategies targeting this mechanism.